Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Down-regulated lncRNA DLX6-AS1 inhibits tumorigenesis through STAT3 signaling pathway by suppressing CADM1 promoter methylation in liver cancer stem cells.

Wu DM, Zheng ZH, Zhang YB, Fan SH, Zhang ZF, Wang YJ, Zheng YL, Lu J.

J Exp Clin Cancer Res. 2019 Jun 6;38(1):237. doi: 10.1186/s13046-019-1239-3.

2.

lncRNA CADM1-AS1 inhibits cell-cycle progression and invasion via PTEN/AKT/GSK-3β axis in hepatocellular carcinoma.

Wang F, Qi X, Li Z, Jin S, Xie Y, Zhong H.

Cancer Manag Res. 2019 Apr 30;11:3813-3828. doi: 10.2147/CMAR.S197673. eCollection 2019.

3.

Long non-coding RNA DLX6-AS1 aggravates hepatocellular carcinoma carcinogenesis by modulating miR-203a/MMP-2 pathway.

Zhang L, He X, Jin T, Gang L, Jin Z.

Biomed Pharmacother. 2017 Dec;96:884-891. doi: 10.1016/j.biopha.2017.10.056. Epub 2017 Nov 6.

PMID:
29145165
4.

Expression of long non-coding RNA DLX6-AS1 in lung adenocarcinoma.

Li J, Li P, Zhao W, Yang R, Chen S, Bai Y, Dun S, Chen X, Du Y, Wang Y, Zang W, Zhao G, Zhang G.

Cancer Cell Int. 2015 May 2;15:48. doi: 10.1186/s12935-015-0201-5. eCollection 2015.

5.

Long noncoding RNA DLX6-AS1 promotes liver cancer by increasing the expression of WEE1 via targeting miR-424-5p.

Li D, Tang X, Li M, Zheng Y.

J Cell Biochem. 2019 Aug;120(8):12290-12299. doi: 10.1002/jcb.28493. Epub 2019 Feb 25.

PMID:
30805988
6.
7.

LncRNA DLX6-AS1 promoted cancer cell proliferation and invasion by attenuating the endogenous function of miR-181b in pancreatic cancer.

An Y, Chen XM, Yang Y, Mo F, Jiang Y, Sun DL, Cai HH.

Cancer Cell Int. 2018 Sep 18;18:143. doi: 10.1186/s12935-018-0643-7. eCollection 2018.

8.

Long non-coding RNA DLX6-AS1 silencing inhibits malignant phenotypes of gastric cancer cells.

Fu X, Tian Y, Kuang W, Wen S, Guo W.

Exp Ther Med. 2019 Jun;17(6):4715-4722. doi: 10.3892/etm.2019.7521. Epub 2019 Apr 23.

9.
10.

Long noncoding RNA DLX6-AS1 promotes tumorigenesis by modulating miR-497-5p/FZD4/FZD6/Wnt/β-catenin pathway in pancreatic cancer.

Yang J, Ye Z, Mei D, Gu H, Zhang J.

Cancer Manag Res. 2019 May 7;11:4209-4221. doi: 10.2147/CMAR.S194453. eCollection 2019.

11.

LncRNA DLX6-AS1 promotes the proliferation, invasion, and migration of non-small cell lung cancer cells by targeting the miR-27b-3p/GSPT1 axis.

Sun W, Zhang L, Yan R, Yang Y, Meng X.

Onco Targets Ther. 2019 May 22;12:3945-3954. doi: 10.2147/OTT.S196865. eCollection 2019.

12.

Decreased expression of a novel lncRNA CADM1-AS1 is associated with poor prognosis in patients with clear cell renal cell carcinomas.

Yao J, Chen Y, Wang Y, Liu S, Yuan X, Pan F, Geng P.

Int J Clin Exp Pathol. 2014 May 15;7(6):2758-67. eCollection 2014.

13.

Down-regulated long non-coding RNA RNAZFHX4-AS1 suppresses invasion and migration of breast cancer cells via FAT4-dependent Hippo signaling pathway.

Li SY, Wang H, Mai HF, Li GF, Chen SJ, Li GS, Liang BC.

Cancer Gene Ther. 2018 Dec 14. doi: 10.1038/s41417-018-0066-6. [Epub ahead of print]

PMID:
30546116
14.

LncRNA DLX6-AS1 promotes tumor proliferation and metastasis in osteosarcoma through modulating miR-641/HOXA9 signaling pathway.

Zhang N, Meng X, Mei L, Zhao C, Chen W.

J Cell Biochem. 2019 Mar 6. doi: 10.1002/jcb.28426. [Epub ahead of print]

PMID:
30838699
15.

Long noncoding RNA DLX6-AS1 functions as a competing endogenous RNA for miR-577 to promote malignant development of colorectal cancer.

Zhou FR, Pan ZP, Shen F, Huang LQ, Cui JH, Cai K, Guo XL.

Eur Rev Med Pharmacol Sci. 2019 May;23(9):3742-3748. doi: 10.26355/eurrev_201905_17800.

16.

Long non-coding RNA FEZF1-AS1 promotes cell invasion and epithelial-mesenchymal transition through JAK2/STAT3 signaling pathway in human hepatocellular carcinoma.

Wang YD, Sun XJ, Yin JJ, Yin M, Wang W, Nie ZQ, Xu J.

Biomed Pharmacother. 2018 Oct;106:134-141. doi: 10.1016/j.biopha.2018.05.116. Epub 2018 Jun 26.

PMID:
29957463
17.

LncRNA DBH-AS1 facilitates the tumorigenesis of hepatocellular carcinoma by targeting miR-138 via FAK/Src/ERK pathway.

Bao J, Chen X, Hou Y, Kang G, Li Q, Xu Y.

Biomed Pharmacother. 2018 Nov;107:824-833. doi: 10.1016/j.biopha.2018.08.079. Epub 2018 Aug 22.

PMID:
30142544
18.

LncRNA DLX6-AS1/miR-129-5p/DLK1 axis aggravates stemness of osteosarcoma through Wnt signaling.

Zhang RM, Tang T, Yu HM, Yao XD.

Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):260-266. doi: 10.1016/j.bbrc.2018.11.019. Epub 2018 Nov 13.

PMID:
30442366
19.

Long noncoding RNA DLX6-AS1 accelerates the glioma carcinogenesis by competing endogenous sponging miR-197-5p to relieve E2F1.

Li X, Zhang H, Wu X.

Gene. 2019 Feb 20;686:1-7. doi: 10.1016/j.gene.2018.10.065. Epub 2018 Oct 23.

PMID:
30366080
20.

EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway.

Lei T, Zhu X, Zhu K, Jia F, Li S.

Cancer Biol Ther. 2019;20(7):1007-1016. doi: 10.1080/15384047.2019.1595276. Epub 2019 Mar 31.

PMID:
30929558

Supplemental Content

Support Center